Detalhe da pesquisa
1.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37354090
2.
Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.
Ann Hematol
; 102(11): 3015-3023, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37535147
3.
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Ann Hematol
; 102(6): 1375-1382, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37079069
4.
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Eur J Haematol
; 111(2): 311-317, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37231885
5.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35137397
6.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
7.
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Ann Hematol
; 101(6): 1275-1282, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35318505
8.
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients.
Support Care Cancer
; 30(5): 4303-4314, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35088150
9.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33794557
10.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33222197
11.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33590502
12.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33617659
13.
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Ann Hematol
; 100(5): 1213-1219, 2021 May.
Artigo
Inglês
| MEDLINE | ID: mdl-33677654
14.
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
Acta Oncol
; 60(11): 1520-1526, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34461798
15.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34499575
16.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31860137
17.
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Hematol Oncol
; 38(2): 189-196, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31891213
18.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32271957
19.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Ann Hematol
; 99(10): 2405-2416, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32813071
20.
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
Ann Hematol
; 99(12): 2773-2777, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32462330